Exjade
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
We report on the development of chronic interstitial nephritis induced by Deferasirox (Exjade). The patient is a 40-yearold woman…
Background and purpose: Exjade is developed by Novartis pharmaceutical company and contains the active substance deferasirox, an…
Objective: To propose a study, which employs the pharmaco-economic approach to prove that Exjade is not only effective medication…
Background: Thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or…
Background: Labile plasma iron (LPI) is a toxic, directly chelatable form of non-transferrin- bound iron that is produced…
Background: The efficacy and safety of deferasirox was established during five 1-year core trials. As many patients will require…
ICL670(deferasirox) is a tridentate oral iron chelator that has shown high efficacy and theraputic safety in preclinical and…
Iron excretion can be calculated according to Angelucci et al (NEJM 2000). As applied to the novel oral iron chelator deferasirox…
Transfusional hemosiderosis is often associated with hepatic siderosis or infection with hepatotropic viruses, resulting in…
Introduction: Although the direct measurement of iron from a liver biopsy is the reference standard method to determine liver…